丰原药业
(000153)
| 流通市值：25.02亿 | | | 总市值：26.03亿 |
| 流通股本：3.19亿 | | | 总股本：3.32亿 |
| 报告期 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 3,224,068,934.15 | 2,285,417,858.93 | 1,206,114,496.19 | 4,004,020,381.58 |
| 营业收入 | 3,224,068,934.15 | 2,285,417,858.93 | 1,206,114,496.19 | 4,004,020,381.58 |
| 二、营业总成本 | 3,054,625,491.37 | 2,156,020,286.08 | 1,145,309,254.54 | 3,849,176,986.5 |
| 营业成本 | 2,376,539,605.19 | 1,666,226,185.61 | 866,359,318.28 | 2,873,748,884.85 |
| 税金及附加 | 27,251,123.62 | 19,115,982.01 | 9,399,351.47 | 32,788,421.53 |
| 销售费用 | 453,203,772.32 | 333,900,217.1 | 200,444,348.75 | 680,471,991.54 |
| 管理费用 | 121,620,386.8 | 80,708,002.25 | 37,097,826.46 | 166,797,830.72 |
| 研发费用 | 55,452,321.19 | 41,387,908.33 | 25,035,890.83 | 65,466,089.63 |
| 财务费用 | 20,558,282.25 | 14,681,990.78 | 6,972,518.75 | 29,903,768.23 |
| 其中:利息费用 | 25,553,676.89 | 17,656,678.18 | 8,980,447.33 | 32,865,467.23 |
| 其中:利息收入 | 5,430,244.35 | 3,111,167.6 | 2,136,088.06 | 5,357,860.93 |
| 加:公允价值变动收益 | -14,371,030.19 | -1,596,034.86 | -137,902.88 | 11,080,248.72 |
| 加:投资收益 | 5,221,805.57 | 14,430.32 | 8.53 | 3,742,202.02 |
| 资产处置收益 | 4,419,177.75 | 4,388,110.41 | 57,661.89 | -248,769.45 |
| 资产减值损失(新) | -3,730,375.24 | -3,365,069.35 | -455,643.75 | -11,089,030.07 |
| 信用减值损失(新) | 4,501,853.61 | -1,557,718.92 | -1,885,683.49 | -3,872,808.16 |
| 其他收益 | 23,433,964.66 | 15,618,034.9 | 7,393,644.14 | 47,642,591.41 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 188,918,838.94 | 142,899,325.35 | 65,777,326.09 | 202,097,829.55 |
| 加:营业外收入 | 1,567,918.81 | 1,081,734.15 | 703,173.66 | 1,257,322.79 |
| 减:营业外支出 | 482,244.01 | 440,178.12 | 287,607.3 | 1,062,661.91 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 190,004,513.74 | 143,540,881.38 | 66,192,892.45 | 202,292,490.43 |
| 减:所得税费用 | 48,673,780.86 | 41,255,996.73 | 20,550,017.29 | 51,351,806.71 |
| 六、净利润 | 141,330,732.88 | 102,284,884.65 | 45,642,875.16 | 150,940,683.72 |
| 持续经营净利润 | 141,330,732.88 | 102,284,884.65 | 45,642,875.16 | 150,940,683.72 |
| 归属于母公司股东的净利润 | 142,464,110.4 | 103,015,799.31 | 46,024,429.74 | 154,426,589.4 |
| 少数股东损益 | -1,133,377.52 | -730,914.66 | -381,554.58 | -3,485,905.68 |
| (一)基本每股收益 | 0.43 | 0.31 | 0.14 | 0.49 |
| (二)稀释每股收益 | 0.43 | 0.31 | 0.14 | 0.49 |
| 八、其他综合收益 | -724,453.83 | 2,405,195.31 | -1,053,939.54 | 3,222,726.72 |
| 归属于母公司股东的其他综合收益 | -896,561.1 | 2,268,733.66 | -1,135,019.89 | 3,011,721.68 |
| 九、综合收益总额 | 140,606,279.05 | 104,690,079.96 | 44,588,935.62 | 154,163,410.44 |
| 归属于母公司股东的综合收益总额 | 141,567,549.3 | 105,284,532.97 | 44,889,409.85 | 157,438,311.08 |
| 归属于少数股东的综合收益总额 | -961,270.25 | -594,453.01 | -300,474.23 | -3,274,900.64 |
| 公告日期 | 2023-10-27 | 2023-08-25 | 2023-04-27 | 2023-04-20 |
| 审计意见(境内) | | | | 标准无保留意见 |